tlooto
Sign up
Open AccessMedicine

Durvalumab after chemoradiotherapy in stage III non-small cell lung cancer.

P. Tomasini, L. Greillier, Arnaud Boyer, Arnaud Jeanson, F. Barlesi

2018.4.16Journal of Thoracic Disease

DOI: 10.21037/jtd.2018.04.61

tlooto Summary

Immune Check Point inhibitors have demonstrated efficacy in advanced stage solid tumors including non-small cell lung cancer (NSCLC), CTLA4, programmed cell death-1 (PD-1) and PD-1 ligand 1 ( PD-L1) inhibitors being the most studied drugs.

Abstract

Abstract is not available.

Citation format

TOMASINI, P., et al. Durvalumab after chemoradiotherapy in stage III non-small cell lung cancer. Journal of Thoracic Disease, 2018, 10 Suppl 9: S1032-S1036.